Potential Therapeutic Value of Palosuran in Renovascular Hypertension and Associated Cardio-vascular and Renal Complications

Abstract

Hypertension is the most common chronic disease in the world and produces substantial morbidity and mortality. Individuals with uncontrolled hypertension are at high risk of stroke, coronary artery disease leading to myocardial infarction, or acute renal failure. Nowadays, treatment of hypertension still remains a topical problem due to theside effects of existing antihypertensive drugs. In recent years,  interest in the cyclic vasoactive neuropeptide urotensin-2 (U-II), which is characterized by strong vasoconstrictor properties, has been increased.Increased secretion of U-II and excessive expression of UT-II receptors have been identified in several pathologies, including hypertension. Using U-II/UTR antagonists remain an attractive target in cardiovascular and renal system pathology. We were aimed to study effect of the UTR antagonist - Palosuran on blood pressure, cardio-vascular system and renal tissue in rats with hypertension (2 kidneys+1 clip).Palosuran was administered intraperitoneally (10 mg/kg once daily, during 4 weeks). Blood pressure was measured non-invasively, using “tail cuff“ method.  Studies have shown that in hypertensive rats Palosuran reveals hypotensive effect,decreases workload on the myocardium and reduces risk of complications. Effect of treatment is better expressed at early stage of hypertension.